

Lithuania

Population (January 2013):	2 971 905
Human development Index (2013):	0.834
HAV vaccine recommendations:	HAV vaccination is not included in the national childhood immunization programme. Vaccination is recommended for: 1. contacts of HAV patients 2. travellers to endemic areas 3. high risk groups.
Seroprevalence studies by quality score:	score 0: 0 studies score 1: 0 study score 2: 1 study
Seroprevalence studies timeframe:	2003

Seroprevalence assessment: **low**
Incidence assessment: **low**
Susceptibility in adults: **moderate**

One study conducted in Lithuania in 2003, estimated HAV seroprevalence to be 55% in the age group 20–29 years and 30% in the age group 10–19 years. There were no available estimates by 30 years or older. Therefore, Lithuania, is likely to be a low endemicity country (Figure 1).

Lithuania_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Reported incidence was above 20/100 000 until 1999 and it has been strongly decreasing since then (Figure 2). TESSy data are consistent with low/very low endemicity picture with a reported incidence oscillating around 2/100 000 since 2006.

In Lithuania, around 40% of the population is susceptible to HAV infection at age 30. Considering the reported incidence, virus circulation was sustained until late 1990s. Therefore, susceptibility levels among older age groups are very likely to be lower. Susceptibility in adults is to be considered moderate.

Lithuania_Figure 1 (panel a). Summary of seroprevalence in Lithuania, by age and time period.


Panel a.1: 1975–1989

No data available

Panel a.2: 1990–1999

No data available

Panel a.3: 2000–2013

**Lithuania_Figure 2. Reported incidence of hepatitis A in Lithuania, 1975–2013***

*National data source: personal communication from ECDC National Focal Point/Operational Contact Point, Centre of Infectious Diseases and AIDS of Lithuania

Bibliography

1. Kurkela S, Pebody R, Kafatos G, Andrews N, Barbara C, Bruzzone B, et al. Comparative hepatitis A seroepidemiology in 10 European countries. *Epidemiol Infect.* 2012 Dec;140(12):2172-81.
2. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. *J Travel Med.* 2007;14(3):181-7.